Subscriber Benefit
As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe NowScioto Biosciences, an Indianapolis-based, preclinical-stage company developing therapies to fight serious conditions in premature infants, has closed on $1.8 million in early-stage financing.
The investors include locally based Elevate Ventures, a private venture development organization; locally based BioCrossroads, a public-private collaboration that supports Indiana’s life-sciences sector; and Ohio-based Rev1 Ventures.
Scioto Biosciences, founded in 2017, is trying to use the technology to combat a condition in premature infants where the wall of the intestine is invaded by bacteria.
“We are delighted that a team of important investors has shown confidence in our microbiome platform technology and sees its commercialization potential,” Scioto Biosciences CEO Joe Trebley said.•
Please enable JavaScript to view this content.